Severe AKI in ICU: Step‑to‑Step Management (Comprehensive Notes)

Severe AKI in ICU: step‑to‑step management (summary notes)

Overview

• AKI = sudden loss of renal function occurring within 7 days, defined by rises in baseline serum creatinine (SCr) and/or reduced urine output. KDIGO 2012 criteria categorize AKI into stages based on SCr changes and urine output; a 2020 consensus added biomarkers to redefine/identify AKI (see Table 1).
• In ICU, AKI prevalence varies: 13–36% in acute heart failure; up to 80% in cardiogenic shock; dialysis‑requiring AKI 5–8%, can exceed 13% in cardiogenic shock. AKI consistently linked to higher short‑ and long‑term mortality and CKD progression.
• Focus of review: step‑by‑step management of severe AKI in ICU patients with fluid overload, from pharmacological therapy to renal replacement therapy (RRT).

Key definitions and constructs

• KDIGO AKI classification (standard) using SCr and urine output (Table 1):
  • Stage 1: SCr increases to 1.5–1.9× baseline or ≥0.3 mg/dL rise; urine output <0.5 mL/kg/h for 6–12 h
  • Stage 2: SCr increases to 2.0–2.9× baseline; urine output <0.5 mL/kg/h for ≥12 h
  • Stage 3: SCr increases to 3.0× baseline or SCr ≥4.0 mg/dL or initiation of RRT; urine output <0.3 mL/kg/h for ≥24 h or anuria ≥12 h
• KDIGO update includes GFR biomarkers (e.g., cystatin C, NGAL) for biomarker‑positive/negative classifications (Table 1B/3B).
• Definitions of biomarkers: NGAL, cystatin C; used to refine diagnosis/prognosis and possibly guide timing of interventions.
• Cardiorenal syndrome types: Type 1 (acute cardiorenal) common in AKI with HF; Type 3 renocardiac syndrome is less common.

Initial approach and confirmation of fluid overload

• Identify reversible causes of AKI early (Graphical abstract): confirm fluid overload clinically and with imaging.
• Point‑of‑care ultrasonography (POCUS) in AKI evaluation:
  • Renal ultrasound: assess kidneys size and echogenicity to rule out intrinsic renal causes; exclude bladder retention.
  • Hemodynamics/volume status: assess filling pressures (congestion) and forward flow (perfusion).
  • Internal jugular vein (IJV) ultrasound: moderate sensitivity/specificity for hypervolemia vs hypovolemia; can be used as an initial approach.
  • LVOT VTI (left ventricular outflow tract velocity time integral): helps identify response to volemic filling.
  • VExUS score (venous congestion assessment combining IVC, hepatic vein, portal vein Dopplers): score ≥1 correlates with AKI, higher diuretic use after 48 h, and poorer prognosis; requires doppler expertise; portal vein Doppler may be particularly helpful for real‑time decongestion monitoring during dialysis.
• Reassessment of ongoing therapies when AKI occurs:
  • Stop nephrotoxic drugs (antimicrobials like aminoglycosides, NSAIDs, etc.). Exclude recent iodinated contrast exposure.
  • Consider continuation/short‑term cautious use of mineralocorticoid receptor antagonists, SGLT2 inhibitors, and ARNI in mild AKI with careful monitoring; emerging data suggest persistence of benefits even with eGFR <30 mL/min/1.73 m² in some trials (DAPA‑HF, DELIVER, PARADIGM‑HF/PARAGON‑HF analyses).
  • Recognize that diuretic/ARNI/SGLT2 continuation may be reasonable in early AKI if patient condition allows, but monitor for hyperkalemia and renal function decline.

Pharmacological management: diuretics and beyond

• Diuretics are cornerstone therapy for fluid overload in AKI with HF; goal is decongestion and maintenance of perfusion.
• Blood pressure/organ perfusion target:
  • Maintain MAP ≥ 65 mmHg to preserve renal perfusion; higher MAP (>80–85 mmHg) may raise cardiac output without improving urine output or creatinine clearance; diuretics may help reduce CVP and improve renal perfusion.
• Inotropes/vasopressors:
  • May be used to maintain MAP and promote nephron perfusion when needed.
• Dopamine (renal dose) is not recommended due to lack of benefit and potential harm.
• Levosimendan: may reduce AKI in some settings (cardiac surgery), but evidence is limited.
• Loop diuretics: central in driving diuresis and reducing congestion; DOSE trial showed no advantage of bolus vs continuous infusion for symptoms/SCr; high‑dose may increase diuresis but can transiently worsen renal function; continuous infusion may benefit haemodynamically unstable patients or require precise titration (with initial IV bolus to reach effective concentration).
• Diuretic resistance: multiple mechanisms including gut congestion, hypotension/low CO, altered pharmacokinetics (protein binding, OAT transport, acidosis), and intrarenal sodium retention; sequential nephron blockade is a rational approach.
• Combination diuretic strategies for resistance:
  • Add thiazide diuretics (chlorothiazide or metolazone) to overcome resistance; CLOROTIC trial showed enhanced diuresis with thiazides; metolazone non‑inferior to chlorothiazide in some contexts; monitor electrolytes and renal function due to electrolyte derangements.
  • Acetazolamide augmentation (ADVOR trial) to enhance proximal NaHCO3 retention and diuretic response; magnifies response in patients with elevated bicarbonate.
  • SGLT2 inhibitors can aid decongestion but have lower natriuretic effect than thiazides; overall disease‑modifying with some diuretic action; combine with loop diuretics as clinically indicated.
• Hypertonic saline solution (HSS) with furosemide in diuretic‑resistant HF: osmotic effect may mobilize interstitial fluid; mechanism includes enhanced chloride/natrium delivery to Henle’s loop; data largely open‑label; SALT‑HF post‑hoc suggests chloride status may modulate benefit; more robust RCTs needed.
• Practical algorithm (Figure 1 in article): stepwise escalation from loop diuretics to advanced measures in diuretic‑resistant, critically ill patients. HSS mentioned as an adjunct option in some contexts.
• Diuretic resistance management take‑home:
  • Start with standard IV furosemide 40 mg in diuretic‑naive or 1–2× home oral dose IV for those on oral therapy.
  • Reassess urine output and natriuresis within 2–6 h; double loop diuretic dose if response is insufficient.
  • Consider sequential nephron blockade (loop + thiazide or other diuretics) and address metabolic acidosis to optimize delivery of diuretics to the nephron.
  • Monitor electrolytes and renal function closely during combination diuretic therapy.
• Role of decongestion monitoring tools:
  • Natriuresis and urine output-guided decongestion strategies to optimize diuretic response; natriuresis‑guided strategies show promise but require further validation.

Ultrafiltration vs pharmacological therapy as first‑line strategy

• CARRESS‑HF trial: ultrafiltration (UF) vs aggressive, urine‑output guided diuretic therapy in acute decompensated HF with AKI showed neutral effect on outcomes; higher incidence of adverse events including worsening renal function in UF; high crossover and drop‑out may have biased results.
• Per‑protocol analyses and follow‑ups suggest UF achieved greater fluid removal and weight loss but often with worse renal markers (elevated SCr/BUN) at 72 h; no clear 60‑day advantage in death or HF hospitalization.
• UNLOAD trial: UF yielded greater early weight loss and fluid removal; lower 90‑day HF hospitalization with UF.
• CUORE trial: UF vs diuretics had similar weight loss; smaller size; fewer HF hospitalizations in follow‑up; renal function stable; generalizability limited due to older age in cohort.
• AVOID‑HF trial: UF vs diuretics in acute HF with cardiorenal syndrome; more decongestion with UF, but 30‑day HF hospitalization reductions; significant sponsor termination and suboptimal decongestion in many UF patients.
• Overall: no robust data to support UF as first‑line therapy for decompensated HF; initial management with pharmacological therapy remains preferred; UF may be considered for refractory congestion or when diuretics fail, or when rapid fluid removal is necessary and diuretic response is poor.

Renal replacement therapy (RRT) in severe AKI

• Indications (AEIOU framework):
  • Acidosis, Electrolyte derangements, Intoxications, Volume overload, Uremia; volume overload with hemodynamic instability is a leading ICU indication (about 65%).
• RRT aims: remove wastes and water, balance electrolytes, and correct acid–base status; CRRT provides solute clearance and volume removal with continuous therapy and is favored in hemodynamically unstable patients.
• CRRT modalities (Table 3):
  • CVVHD: Diffusion‑based clearance; no replacement fluid requirement; less volume removal.
  • CVVH: Convective clearance; requires replacement fluid; more aggressive volume control.
  • CVVHDF: Combines convection and diffusion; balance between volume control and solute removal; higher cost.
• Timing of CRRT: no clear benefit of early CRRT initiation vs wait‑and‑see in severe AKI; early CRRT increases hypotension and infection events in some analyses. Consider CRRT when there is refractory symptomatic fluid overload or clear indications; monitor SCr trend to guide timing. Preemptive evaluation for CRRT indications should occur as AKI progresses to stage II.
• CRRT management: tips and tricks (Figure 2)
  • Vascular access: large‑diameter dual‑lumen catheter; IJV preferred (right side) for direct path to RA; alternatives include femoral or axillary access; ultrasound guidance recommended to reduce placement complications.
  • CRRT dose, blood flow rate, and net ultrafiltration (UF): KDIGO recommends 25–30 mL/kg/h as delivered dose; select blood flow 150–250 mL/min in adults; higher flows may cause hypotension; UF rate should be tailored to decongestion needs and hemodynamic tolerance; net UF has a U‑shaped relation to mortality with best outcomes around 1.0–1.75 mL/kg/h.
  • Anticoagulation: regional citrate anticoagulation (RCA) is preferred due to better circuit life and lower bleeding risk; target citrate 3–4 mmol/L with ionized calcium 0.25–0.4 mmol/L; systemic calcium replacement is required; liver failure or profound shock may require adjusted citrate doses; alternative is unfractionated heparin (UFH) with its pros/cons (cost, reversibility, HIT risk).
  • Electrolyte monitoring and nutrition: monitor total and ionized calcium, phosphorus, magnesium every 6–12 h; critically ill AKI patients are catabolic and require protein supplementation per consensus; monitor and adjust nutrients and electrolyte balance during therapy.
  • Drug pharmacokinetics during CRRT: many drugs' clearance is altered by CRRT; most inotropes/vasopressors are not significantly cleared by CRRT, but dosing may still require adjustment; milrinone and levosimendan metabolites may accumulate or have prolonged half‑lives; antibiotics often require higher/alternate dosing; adjust doses based on drug properties, CRRT modality, blood flow, diet/volume status. Typical caution: milrinone may accumulate (half‑life up to ~20 h in CRRT); levosimendan metabolites prolonged; dose adjustments guided by pharmacokinetic resources and team consensus.
• CRRT discontinuation and weaning
  • Weaning success depends on CKD status, duration of CRRT, and urine output at cessation; higher urine output and lower SCr/urea at cessation predict success; diuretics to enhance urine output after CRRT cessation may help but evidence is limited; consider a “diuretic holiday” during weaning with careful monitoring.
  • Weaning criteria: increased diuresis (thresholds ~436 mL/24 h without diuretics; ~2330 mL/24 h with diuretics); low SCr and low serum urea may predict weaning success; monitor for CRRT continuity decisions.
  • After CRRT cessation, transitioning strategies include shifting to intermittent dialysis if needed; if diuretic response is adequate, continue diuretic therapy post‑CRRT with close monitoring.
• Complications of CRRT (Table 4 and Fig. 3):
  • Vascular access complications; infection risk; catheter‑related issues; HIT with heparin; systemic anticoagulation challenges; hypotension and hypothermia during CRRT; cytokine activation and inflammatory responses; acid–base and electrolyte disturbances (calcium, phosphate, magnesium); citrate toxicity risk with RCA; volume depletion and hypotension may require fluid management adjustments; thermal losses can cause hypothermia; nutritional losses require protein/calorie management; circuit clotting; haematologic issues including anemia and HIT risk with UFH; dialysis disequilibrium syndrome (DDS) rarely with CRRT but noted.
  • Neurological and cardiac concerns: cardiac stunning in CRRT initiation; monitor for DDS in rapid solute shifts.
• Weaning and transition in practice
  • Tissue/clinical indicators and urine output are the main guides for CRRT discontinuation; ensure renal recovery adequate to tolerate drop in CRRT support; monitor electrolytes, acid–base, and hemodynamics; transition to intermittent dialysis when appropriate.

Evidentiary highlights and trials

• CARRESS‑HF (UF vs diuretic decongestion): UF did not improve outcomes versus diuretics; worse decongestion markers and higher adverse events in UF arm; cross‑over and drop‑out problematic; suggests UF not superior as first‑line in acute HF with AKI.
• UNLOAD and CUORE: UF showed early fluid removal benefits and reduced HF hospitalizations in some long‑term follow‑ups, but results are inconsistent and population heterogeneity limits generalizability.
• AVOID‑HF: UF reduced congestion acutely but did not clearly improve short‑term mortality; sponsor termination and mixed results.
• ADVOR (acetazolamide addition to loop diuretic therapy): improved decongestion in acute decompensated HF with volume overload; magnified response when baseline HCO3 elevated; supports acetazolamide as adjunct in diuretic resistance.
• CLOROTIC and metolazone/chlorothiazide strategies: demonstrated improved diuretic response in loop diuretic resistance; caution with electrolytes/renal function.
• SGLT2 inhibitors in resistant HF: mixed evidence; may enhance decongestion with disease‑modifying benefits; some trials show preserved or enhanced diuresis with SGLT2 inhibitors, but diuretic response differs from thiazides.
• Hypertonic saline strategies: multiple studies show improved diuresis and renal safety in some settings; SALT‑HF suggests chloride level may mediate benefits; evidence remains inconclusive; more robust double‑blind trials needed.
• Relevance to practice: RRT timing should be individualized; early CRRT does not consistently reduce mortality; in many patients, a watchful waiting approach with optimized medical therapy is reasonable until clear indications for CRRT arise.

KDIGO and biomarker guidance, and future research gaps (Table 4)

• KDIGO remains a cornerstone for AKI staging and management with an emphasis on careful fluid management, avoidance of nephrotoxins, and consideration of RRT when indicated.
• Biomarkers (cystatin C, NGAL, IL‑18, IL‑6, osteopontin) add prognostic value and may guide risk stratification; their integration into routine practice remains an area of active investigation.
• Future research areas identified in Table 4 include: pharmacological therapy optimization in refractory AKI–DI, CRRT modality selection and dosing (including obesity), timing of CRRT initiation and biomarker‑based risk stratification, strategies for CRRT discontinuation and transition to long‑term dialysis, minimizing CRRT complications, and better pathways for diuretic holidays and deprescription during CRRT cessation.

Clinical pearls and practical takeaways

• Early and accurate assessment of fluid overload is critical; use standardized ultrasound markers (VExUS, LVOT VTI, IVC) to guide fluid removal decisions.
• Diuretics remain first‑line for congestion; titrate carefully, monitor urine output, and consider sequential nephron blockade (loop + thiazide) or adjunct agents (acetazolamide, SGLT2 inhibitors) in diuretic resistance.
• UF/CRRT should not be the default first‑line therapy for HF‑related AKI with fluid overload; reserve for refractory cases or when rapid, controlled fluid removal is needed and diuretics fail.
• CRRT requires meticulous planning: choose modality based on hemodynamics, optimize anticoagulation (prefer RCA when feasible), monitor electrolytes, nutrition, and drug dosing, and plan for weaning as renal recovery occurs.
• Monitor for CRRT complications and prepare for potential transitions to intermittent dialysis or outpatient dialysis if long‑term kidney function does not recover.

Key numerical references to remember (LaTeX format)

• AKI definition window: AKI occurs within $7 ext{ days}$ of renal function decline.
• KDIGO stages (SCr and urine output):
  • Stage 1: ext{SCr}: ext{Increase to } 1.5-1.9 imes ext{baseline} ext{ or } riangle ext{SCr} ext{ ≥ } 0.3 ext{ mg/dL}; ext{Urine output}: <0.5 ext{ mL/kg/h for } 6-12 ext{ h}
  • Stage 2: ext{SCr}: 2.0-2.9 imes ext{baseline}; ext{Urine output}: <0.5 ext{ mL/kg/h for } ext{≥12 h}
  • Stage 3: ext{SCr}: 3.0 imes ext{baseline} ext{ or } ext{SCr} ext{ ≥ } 4.0 ext{ mg/dL} ext{ or initiation of RRT}; ext{Urine output}: <0.3 ext{ mL/kg/h for } ext{≥24 h or anuria ≥12 h}
• CRRT dose (delivered): 25-30 rac{ ext{mL}}{ ext{kg} ext{·} ext{h}}
• Blood flow rate for CRRT: 150-250 rac{ ext{mL}}{ ext{min}}
• Net UF rate with favorable mortality: 1.0-1.75 rac{ ext{mL}}{ ext{kg} ext{·} ext{h}}
• RCA citrate targets: citrate blood concentration $3-4 ext{ mmol/L}$; ionized calcium ${0.25-0.4 ext{ mmol/L}}$; systemic calcium replacement as needed.

Notes on references and scope

• Trials and guidelines cited (CARRESS‑HF, UNLOAD, CUORE, AVOID‑HF, ADVOR, CLOROTIC, etc.) inform the relative benefits/risks of UF vs diuretics, and adjunctive diuretic strategies.
• The review emphasizes a multi‑step, fluid‑overload–driven approach to severe AKI in ICU, with pharmacologic decongestion as the initial strategy, escalating to CRRT when indicated by hemodynamics, fluid balance, and renal recovery trajectory.
• The content integrates foundational nephrology principles with cardio‑renal interactions, reflecting contemporary ESC/AKI guidelines and pivotal RRT trials.

Connections to foundational principles

• Cardiorenal interplay: congestion and venous congestion contribute to AKI; improving forward flow and reducing venous pressures improves renal perfusion.
• Osmotic and hemodynamic strategies for decongestion: combining diuretics with approaches like acetazolamide and HSS attempts to optimize diuretic response and fluid removal while preserving renal perfusion.
• Balancing risks/benefits of CRRT: early aggressive decongestion may come at cost of hypotension and circuit complications; careful patient selection and multidisciplinary management are essential.
• Ethical and practical implications: in resource‑intensive ICU settings, decisions about UF vs diuretics, timing of CRRT, and transitions to long‑term dialysis have profound impacts on outcomes and quality of life. Multidisciplinary care and shared decision making are essential.